

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
31 March 2022 (31.03.2022)



(10) International Publication Number
WO 2022/067255 A2

(51) International Patent Classification:
A61K 39/085 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:
PCT/US2021/052418

Published:

— without international search report and to be republished
upon receipt of that report (Rule 48.2(g))

(22) International Filing Date:
28 September 2021 (28.09.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/084,273 28 September 2020 (28.09.2020) US

(71) Applicants: **JANSSEN PHARMACEUTICALS, INC.**
[US/US]; 1125 Trenton-Harbourton Rd., Titusville, NJ
08560 (US). **NEW YORK UNIVERSITY** [US/US]; 70
Washington Square South, New York, NY 10012 (US).

(72) Inventors: **MORROW, Brian**; 1000 US Highway 202,
Raritan, NJ 08869 (US). **KONSTANTINOV, Sergey**;
Archimedesweg 4-6, 2333 CN Leiden (NL). **GEURTSEN,**
Jeroen; Archimedesweg 4-6, 2333 CN Leiden (NL). **LUO,**
Jinquan; 1400 McKean Road, Spring House, PA 19477
(US). **SOMANI, Sandeep**; 1400 McKean Road, Spring
House, PA 19477 (US). **BUCKLEY, Peter T.**; 1400 McK-
ean Road, Spring House, PA 19477 (US). **TORRES, Victor**
J.; 564 1st Avenue, Apt. 23E, New York, NY 10016 (US).

(74) Agent: **CHILDS, Carissa R.** et al.; Troutman Pepper
Hamilton Sanders, 70 Linden Oaks, Suite 210, Rochester,
NY 14625 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: VARIANT *STAPHYLOCOCCUS AUREUS* LUKA AND LUKB POLYPEPTIDES AND VACCINE COMPOSITIONS

(57) Abstract: The present disclosure relates to *Staphylococcus aureus* leukocidin A (LukA) and leukocidin B (LukB) variant polypeptides, and polynucleotides encoding the LukA, LukB and LukAB variant polypeptides. The present disclosure further relates to vaccine compositions comprising these LukA and LukB variants, and methods of generating an immune response against *Staphylococcus aureus* in a subject.

WO 2022/067255 A2